...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Report Of Exempt Distribution.
Reply New Message
Back To Forum List View
Report Of Exempt Distribution.
3
KOO-KOO2
Apr 16, 2024 03:39PM
Icon president Re: Report Of Exempt Distribution.
7
Nextblockbuster
Apr 16, 2024 07:13PM
Re: Report Of Exempt Distribution.
1
fuzzyjr
Apr 16, 2024 07:45PM
Re: Report Of Exempt Distribution.
4
jonzobot
Apr 17, 2024 03:58PM
Re: Report Of Exempt Distribution.
3
KOO-KOO2
Apr 17, 2024 04:17PM
Re: Report Of Exempt Distribution.
1
fuzzyjr
Apr 17, 2024 04:33PM
Re: Report Of Exempt Distribution.
1
KOO-KOO2
Apr 17, 2024 05:04PM
Re: Report Of Exempt Distribution.
1
fuzzyjr
Apr 17, 2024 05:45PM
Re: Report Of Exempt Distribution.
2
jonzobot
Apr 17, 2024 07:10PM
Re: Report Of Exempt Distribution.
1
fuzzyjr
Apr 17, 2024 07:27PM
Re: Report Of Exempt Distribution.
2
tada
Apr 18, 2024 12:30AM

tada, should Resverlogix fail, the royalty-preferred shares are worth zero.

Zenith can survive with or without Resverlogix's royalty-preferred shares. Zenith is not dependent on RVX's survival.

I'm still betting that Resverlogix will survive. My glass is still half full for RVX!

 

Koo

2 Recommendations
Re: Report Of Exempt Distribution.
3
fuzzyjr
Apr 18, 2024 09:20AM
Re: Report Of Exempt Distribution.
2
KOO-KOO2
Apr 21, 2024 05:44AM
Re: Report Of Exempt Distribution.
2
KOO-KOO2
Apr 21, 2024 07:37AM
Re: Report Of Exempt Distribution.
1
KOO-KOO2
Apr 30, 2024 06:30AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply